HONG KONG – While prominent household names like Hanmi Pharmaceutical Co. Ltd, Celltrion Inc. and Samsung Biologics Co. Ltd. seem to be hogging the global stage, inking large numbers of out-licensing deals worth billions, lesser-known South Korean drugmakers are also looking outward – just not in the same direction.